SG10201903630UA - Iminosugars useful for the treatment of viral diseases - Google Patents

Iminosugars useful for the treatment of viral diseases

Info

Publication number
SG10201903630UA
SG10201903630UA SG10201903630UA SG10201903630UA SG10201903630UA SG 10201903630U A SG10201903630U A SG 10201903630UA SG 10201903630U A SG10201903630U A SG 10201903630UA SG 10201903630U A SG10201903630U A SG 10201903630UA SG 10201903630U A SG10201903630U A SG 10201903630UA
Authority
SG
Singapore
Prior art keywords
iminosugars
useful
treatment
viral diseases
viral
Prior art date
Application number
SG10201903630UA
Inventor
Urban Ramstedt
Kelly Lyn Warfield
Anthony Treston
Original Assignee
Emergent Virology Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emergent Virology Llc filed Critical Emergent Virology Llc
Publication of SG10201903630UA publication Critical patent/SG10201903630UA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

IMINOSUGARS USEFUL FOR THE TREATMENT OF VIRAL DISEASES Formula IA, and their use for treating viral infections.
SG10201903630UA 2014-11-05 2015-11-04 Iminosugars useful for the treatment of viral diseases SG10201903630UA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462075505P 2014-11-05 2014-11-05

Publications (1)

Publication Number Publication Date
SG10201903630UA true SG10201903630UA (en) 2019-05-30

Family

ID=54542590

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201903630UA SG10201903630UA (en) 2014-11-05 2015-11-04 Iminosugars useful for the treatment of viral diseases
SG11201703330YA SG11201703330YA (en) 2014-11-05 2015-11-04 Iminosugars useful for the treatment of viral diseases

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201703330YA SG11201703330YA (en) 2014-11-05 2015-11-04 Iminosugars useful for the treatment of viral diseases

Country Status (8)

Country Link
US (1) US10428022B2 (en)
EP (1) EP3215499B1 (en)
JP (1) JP6826986B2 (en)
CN (1) CN107207477B (en)
BR (1) BR112017008898B1 (en)
CA (1) CA2966893C (en)
SG (2) SG10201903630UA (en)
WO (1) WO2016073652A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017201052A1 (en) * 2016-05-16 2017-11-23 Emergent Virology Llc Methods of treating zika virus infection

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2834122A1 (en) 1978-08-03 1980-02-14 Bayer Ag METHOD FOR PRODUCING 6-AMINO-6-DESOXY-L-SORBOSE
DE2853573A1 (en) 1978-12-12 1980-07-03 Bayer Ag PREPARATION OF N-SUBSTITUTED DERIVATIVES OF L-DESOXYNOJIRIMYCIN
DE3038901A1 (en) 1980-10-15 1982-05-06 Bayer Ag, 5090 Leverkusen METHOD FOR PRODUCING N-SUBSTITUTED DERIVATIVES OF 1-DESOXYNOJIRIMYCIN
DE3611841A1 (en) 1986-04-09 1987-10-15 Bayer Ag METHOD FOR PRODUCING 1-DESOXYNOJIRIMYCIN AND ITS N-DERIVATIVES
DE3737523A1 (en) 1987-11-05 1989-05-18 Bayer Ag USE OF SUBSTITUTED HYDROXYPIPERIDINES AS ANTIVIRAL AGENTS
US5043273A (en) 1989-08-17 1991-08-27 Monsanto Company Phosphorylated glycosidase inhibitor prodrugs
US5103008A (en) 1989-08-17 1992-04-07 Monsanto Company Compound, N-butyl-deoxynojirimycin-6-phosphate
US4994572A (en) 1989-10-12 1991-02-19 Monsanto Company Synthesis of nojirimycin derivatives
US5200523A (en) 1990-10-10 1993-04-06 Monsanto Company Synthesis of nojirimycin derivatives
AU1876095A (en) 1994-02-25 1995-09-11 G.D. Searle & Co. Use of 1-deoxynojirimycin and its derivatives for treating mammals infected with respiratory syncytial virus
CN1290168A (en) 1997-12-11 2001-04-04 牛津大学院长校长专家委员会 Inhibition of membrane-associated viral replication
US6689759B1 (en) 1998-02-12 2004-02-10 G. D. Searle & Co. Methods of Treating hepatitis virus infections with N-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds in combination therapy
MY122185A (en) 1998-02-12 2006-03-31 Searle & Co Use of n-substituted-1, 5-dideoxy-1, 5-imino-d-glucitol compounds for treating hepatitis virus infections
GB9828474D0 (en) 1998-12-24 1999-02-17 British Aerospace Surface topology inspection
ATE402701T1 (en) 1999-02-12 2008-08-15 United Therapeutics Corp N-(8,8,8-TRIFLUOROOCTYL)-1,5-DIDEOXY-1,5-IMINO- - GLUCITOL FOR THE TREATMENT OF HEPATITIS VIRUS INFECTIONS
WO2004007453A1 (en) * 2002-07-17 2004-01-22 Oxford Glycosciences (Uk) Ltd Piperidinetriol derivatives as inhibitors of glycosylceramide synthase
KR20080025373A (en) * 2005-05-17 2008-03-20 아미쿠스 세라퓨틱스, 인코포레이티드 A method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives
CN101355971A (en) * 2005-05-17 2009-01-28 阿米库斯治疗学公司 Method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives
CN104876855A (en) 2006-05-24 2015-09-02 联合治疗公司 Deoxynojirimycin And D-arabinitol Analogs And Methods Of Using
CN102727437A (en) 2006-08-02 2012-10-17 牛津大学院长校长专家委员会 Liposome treatment of viral infections
WO2009118658A2 (en) 2008-03-26 2009-10-01 University Of Oxford Endoplasmic reticulum targeting liposomes
JP5600329B2 (en) 2009-02-23 2014-10-01 ユナイテッド セラピューティクス コーポレーション Methods for treating iminosugars and viral diseases
WO2010109330A2 (en) 2009-03-27 2010-09-30 University Of Oxford Cholesterol level lowering liposomes
ES2524361T3 (en) * 2009-06-12 2014-12-05 United Therapeutics Corporation Iminoazúcares for use in the treatment of bunyavirus and togavirus diseases
JP5653438B2 (en) 2009-09-04 2015-01-14 ユナイテッド セラピューティクス コーポレイション Treatment of orthomyxovirus infection
US20110065753A1 (en) 2009-09-04 2011-03-17 United Therapeutics Corporation Methods of treating poxviral infections
WO2011028779A1 (en) 2009-09-04 2011-03-10 United Therapeutics Corporation Iminosugars and methods of treating filoviral diseases
KR20150128899A (en) 2013-03-15 2015-11-18 유니터 바이롤로지, 엘엘씨 Antibacterial compounds
US20160075651A1 (en) 2013-05-02 2016-03-17 Unither Virology, Llc Glycolipid inhibition using iminosugars
EP2991657A4 (en) 2013-05-02 2017-02-22 The Chancellor, Masters and Scholars of The University of Oxford Lipidomic biomarkers
SG11201601646YA (en) 2013-09-16 2016-04-28 Emergent Virology Llc Deoxynojirimycin derivatives and methods of their using

Also Published As

Publication number Publication date
EP3215499A1 (en) 2017-09-13
US10428022B2 (en) 2019-10-01
CN107207477A (en) 2017-09-26
JP6826986B2 (en) 2021-02-10
SG11201703330YA (en) 2017-05-30
WO2016073652A1 (en) 2016-05-12
CN107207477B (en) 2022-11-01
US20180273473A1 (en) 2018-09-27
JP2017533962A (en) 2017-11-16
BR112017008898B1 (en) 2022-11-29
BR112017008898A2 (en) 2017-12-19
CA2966893C (en) 2023-10-24
CA2966893A1 (en) 2016-05-12
WO2016073652A8 (en) 2017-05-04
EP3215499B1 (en) 2021-01-20

Similar Documents

Publication Publication Date Title
HRP20190580T1 (en) Combination therapy for treatment of resistant bacterial infections
MX2017001587A (en) Combination therapy for treating a paramyxovirus.
MX2016013689A (en) 4-amino-imidazoquinoline compounds.
MY192927A (en) Fused bicyclic compounds for the treatment of disease
EP3102225A4 (en) Combination therapy for treatment of hbv infections
GB2541571A (en) Pharmaceutical compositions
PH12017500393A1 (en) Pyrrolopyrimidines for use in influenza virus infection
MX2017008456A (en) Fused bicyclic compounds for the treatment of disease.
EA030204B8 (en) Isoindoline derivatives for use in the treatment of a viral infection
EA201790687A1 (en) QUINOLINCARBOXAMIDE FOR USE IN THE TREATMENT OF MULTIPLE MYELOMA
PH12017500602A1 (en) Methods for treating ocular conditions
MX2018005987A (en) Heterocyclic compounds for the treatment of disease.
IL249502A0 (en) Novel therapeutic uses of benzylideneguanidine derivatives for the treatment of proteopathies
PH12016502480A1 (en) Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases
SG10201903630UA (en) Iminosugars useful for the treatment of viral diseases
EP3148538A4 (en) Cenicriviroc for the treatment of hiv-2 infection
MX2015016167A (en) Treatment of polypoidal choroidal vasculopathy.
EA201692164A1 (en) MEDICINE FOR THE TREATMENT OF PATIENTS WITH TINNITUS
MX2017005669A (en) Benzylhydroxyde derivatives, preparation thereof and therapeutic use thereof.
UA100460U (en) APPLICATION OF NOOPHEN AS A MEANS OF TREATMENT OF Erectile Dysfunction in Mono- or Complex Therapy
TH1501006890A (en) Pyridone derivatives for the treatment of additional viral infections and diseases.